A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher. Read MoreDr. Andrew Frank said he is hopeful that the drug will be covered through private health plans. A small number of Canadians are paying for the costly drug themselves. Local News A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher. Read More